CRISPR Therapeutics AG (CRSP)

38.57
0.11 0.28
NASDAQ
Prev Close 38.68
Open 38.93
Day Low/High 37.83 / 39.00
52 Wk Low/High 22.22 / 73.90
Volume 370.75K
Exchange NASDAQ
Shares Outstanding 52.64B
Market Cap 1.96B
Div & Yield N.A. (N.A)

Latest News

Illumina Could Rally to Break Its Downtrend

Illumina Could Rally to Break Its Downtrend

Here's how we would play ILMN stock right now.

Yeti Holdings, Cronos Group, Manitowoc: 'Mad Money' Lightning Round

Yeti Holdings, Cronos Group, Manitowoc: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Yeti Holdings, Cronos Group, Manitowoc, Crispr Therapeutics, Palo Alto Networks, Etsy and more.

China Deal or No Deal?: Cramer's 'Mad Money' Recap (Monday 2/11/19)

China Deal or No Deal?: Cramer's 'Mad Money' Recap (Monday 2/11/19)

Cramer's got the winners, the losers and the wild cards in the China trade brouhaha.

Interesting CRSP Put And Call Options For February 2019

Interesting CRSP Put And Call Options For February 2019

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new February 2019 contracts and identified one put and one call contract of particular interest.

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Jim Cramer says it'll be hard for stocks to stabilize until the Fed's stance softens. He's got your game plan for next week.

Camping World, American Electric Power: 'Mad Money' Lightning Round

Camping World, American Electric Power: 'Mad Money' Lightning Round

Jim Cramer takes a look at Camping World, American Electric Power, Avangrid, Dominion Energy, Thor Industries, Spectrum Pharmaceuticals and more.

Beware the Roving Bear: Cramer's 'Mad Money' Recap (Wednesday 9/12/18)

Beware the Roving Bear: Cramer's 'Mad Money' Recap (Wednesday 9/12/18)

Jim Cramer says September brings out the bear in the market and it's searching how to take your money away. Stay diversified and stay the course, he says.

Prudential, Roku, CRISPR Therapeutics: 'Mad Money' Lightning Round

Prudential, Roku, CRISPR Therapeutics: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Prudential, Roku, CRISPR Therapeutics, Oneok, At Home Group, iQIYI, and TransEnterix.

Market's Leap of Faith: Cramer's 'Mad Money' Recap (Wednesday 8/8/18)

Market's Leap of Faith: Cramer's 'Mad Money' Recap (Wednesday 8/8/18)

Jim Cramer talks about which companies and CEOs are being given the benefit of the doubt -- and which actually deserve it.

Visa, Zuora, CRISPR, Tractor Supply: 'Mad Money' Lightning Round

Visa, Zuora, CRISPR, Tractor Supply: 'Mad Money' Lightning Round

Jim Cramer weighs in on Visa, Zuora, CRISPR, Tractor Supply, Enable Midstream Partners, Eagle Materials, Sempra Energy.

Interesting CRSP Put And Call Options For November 30th

Interesting CRSP Put And Call Options For November 30th

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the November 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new November 30th contracts and identified one put and one call contract of particular interest.

Interesting CRSP Put And Call Options For November 23rd

Interesting CRSP Put And Call Options For November 23rd

Investors in CRISPR Therapeutics AG saw new options become available today, for the November 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new November 23rd contracts and identified one put and one call contract of particular interest.

First Week Of September 21st Options Trading For CRISPR Therapeutics (CRSP)

First Week Of September 21st Options Trading For CRISPR Therapeutics (CRSP)

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Snap, Gilead Sciences, Cronos Group: 'Mad Money' Lightning Round

Snap, Gilead Sciences, Cronos Group: 'Mad Money' Lightning Round

Jim Cramer takes a look at Snap, Gilead Sciences, Cronos Group, TrustCo Bank, CRISPR Therapeutics, Iron Mountian, Prudential and more.

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

Trump's doubling down on trade issues. If you can't stand the pressure, then raise cash. Jim Cramer has your game plan for next week.

Intellia Therapeutics Has Upside in Its DNA

Intellia Therapeutics Has Upside in Its DNA

The setup here is appealing enough to take a small, aggressive shot on the long side.

First Week Of CRSP January 2019 Options Trading

Investors in CRISPR Therapeutics AG saw new options begin trading this week, for the January 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.

CRSP Crosses Above Average Analyst Target

In recent trading, shares of CRISPR Therapeutics AG have crossed above the average analyst 12-month target price of $62.20, changing hands for $65.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FF, FSLR, GVP, IMMR, QBAK, RGNX, SSRM, VSH Downgrades: COMM, CRSP, IMKTA, LBRDA, WIT Initiations: KRP, NAOV Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.

TheStreet Quant Rating: D (Sell)